High levels of activity of the renin-angiotensin system (RAS) and sympathetic nervous system (SNS) are related to left ventricular hypertrophy (LVH). A percentage of subjects with hyperactivity to treadmill stress test show LVH to echocardiogram. This paper aims at evaluating neurohumoral influence over these subjects by comparing drugs that block both the RAS and the SNS. In a 1-year open protocol, 195 normotensive subjects, with hyperactivity to treadmill stress test and LVH, were randomly assigned to supervised physical exercise, rilmenidine 1 mg day
Introduction
Left ventricular hypertrophy (LVH) as detected by echocardiogram is an independent predictor of morbidity and mortality in subjects with high blood pressure 1 and in the population at large. 2 In the adult population there is a modest correlation between casual measurement of blood pressure and LVH. 3, 4 Left ventricular hypertrophy may precede sustained arterial hypertension. Some papers showed that normotensive subjects with exaggerated blood pressure response to physical effort were highly likely to develop sustained arterial hypertension later on, 5, 6 as well as high prevalence of LVH. 7 There are divergences regarding neurohumoral influence over LVH in this specific group of subjects, with some data in the literature pointing out to sympathetic hyperactivity as a triggering factor. 8 Nevertheless, there seems to be an independent and significant correlation between the aldosteron/renin ratio and an increase in systolic blood pressure (SBP) during exercise. 9 Physical exercise reduces blood pressure in prehypertensive subjects. 10 It is likely that improvements in the sympathetic nervous system (SNS), renin-angiotensin-aldosterone system and endothelial function are involved. 11, 12 Nevertheless, there is no evidence of left ventricular mass reduction with physical exercise.
This paper aims at evaluating the neurohumoral influence over these subjects by comparing physical exercise, drugs that block the SNS and drugs that block the renin-angiotensin system (RAS).
Materials and methods

Study population
Both selection of participants and complementary examinations were carried out at the Policia Militar do Espirito Santo policlinic and at Santa Casa de Misericordia de Vitoria Hospital. Healthy police force personnel referred for periodic medical evaluation, aged 25-60 years, white or mixed race, considered normotense at rest according to the criteria of the Sixth Joint National Committee 13 and with SBP X220 mm Hg at stress test were invited to participate in a 1-year open protocol. After consenting to enter the protocol, subjects with SBP p140 mm Hg and DBP p90 mm Hg, body mass index p30 g m À2 , abdominal circumference p88 cm for women and p102 cm for men, maximum SBP at treadmill stress test X220 mm Hg, left ventricular mass index (LVMI) 4120 g m À2 for women and 4150 g m À2 for men were included in the study. Subjects were withdrawn from the protocol if any of the following criteria were present: black, BMIX30 kg m À2 , women with abdominal circumference 488 cm and men with abdominal circumference 4102 cm, SBP at rest 4140 mm Hg and DBP 490 mm Hg, endocrine and/or metabolic diseases, including diabetes, thyroid or collagen, hepatic or renal dysfunction, chronic use of corticosteroids, neuroleptics, tricyclic antidepressive agents, lithium or other drugs that may interfere or interact with the drugs used in the protocol, orovalvular diseases or other cardiac pathologies that make it hard or interfere with ventricular wall measures or cavity diameters in echocardiograms, severe cardiac arrhythmias or atrial fibrillation. Withdrawal of subjects from the protocol was also dependent on subject's will; collateral effects that would make it difficult or even hinder the proposed therapeutic scheme; and development of hypersensitivity to drugs and protocol deviation from the proposed therapeutic scheme.
Study design
After initial tests were carried out, all 245 subjects satisfying the inclusion criteria were randomly assigned to five groups: physical exercise group, undergoing supervised physical exercise; rilmenidine group, treated with rilmenidine 1 mg day À1 orally; atenolol group, treated with atenolol 50 mg day À1 orally; enalapril group, treated with enalapril 10 mg day À1 orally; and losartan group, treated with losartan 50 mg day À1 . All drugs were used in their original presentation forms commercially available. This therapeutic scheme was kept for 12 months, with subjects re-evaluated on a monthly basis to check for adherence to treatment and collateral effects of drugs. In the physical exercise group, only those who had completed the training period with a minimum of 85% of participation in sessions were included in the study results. All subjects included in the study underwent cardiologic clinic test, routine biochemical tests, electrocardiogram, treadmill stress test and two-dimensional Doppler echocardiogram at the first visit and after 12 months of treatment. The study was approved by the Ethics Committees of the Heart Institute (InCor), University of São Paulo Medical School, and of all other participating centers. All participants gave their oral and written informed consent.
Clinical cardiologic evaluation
In addition to arterial hypertension history, the other main risk factors evaluated were obesity, dyslipidemia, tabagism, diabetes and intolerance to glucose. All subjects had their blood collected for evaluation of glucose, sodium, potassium, urea and creatinine concentrations, as well as complete blood test, total cholesterol and fractions, triglycerides and uric acid. Clinical measurements of blood pressure were carried out with a conventional mercury column sphygmomanometer, calibrated and easy to read, with phases 1 and 5 of Korotkoff sounds as basis for SBP and DBP, respectively. Before measurement, all subjects remained seated for 10 min on a comfortable place. Two measurements were taken within 2 min. For data analysis, the average of two measurements was taken into account. Heart rate was calculated by the average of radial pulse palpation for 30 s right after blood pressure measurement was taken.
Treadmill stress test
Tests were carried out on an Inbramed KT 10200 treadmill (Gravataí, RS, Brazil), with continuous monitoring of cardiac frequency by means of the RR waves interval obtained by eletrocardiogram, with simultaneous derivations MC5, D2M and V2M (TEB system, SM 400). The protocol used for work loads was Bruce.
14 All tests were carried out by cardiologists fully trained on the method. Those tests with doubts regarding peak effort were either repeated or disregarded. The criteria for acceptance of a test as maximum followed the guidances proposed in the literature, 15, 16 which include voluntary exhaustion or maximum heart rate at least 90% of the one anticipated for the age group (220Àage). In an attempt to minimize variables that might interfere with interpretation of the results attained, besides the same protocol standards, conditions closest to the first test regarding timetable and test room conditions were reproduced in the retest. 17, 18 Blood pressure measurement was taken at the brachial artery. Heart rate at rest and peak effort, SBP at rest and peak effort, DBP at rest and peak effort, maximum oxygen consumption as well as eletrocardiogram changes were evaluated in the treadmill stress test.
Echocardiographic measurements
An RT 6800 GE (NJ, USA) device was used, with a 2-3 MHz transducer, for color Doppler and M-mode after a 15-min rest. The transducer was positioned in an optimal window, in the left parasternum, towards the short axis of the transverse plane of the papillary muscle of the mitral valve. Measurements were carried out at the end of the diastolic period. Tests were performed by an experienced examiner who was not acquainted with the work protocol. Tests were recorded and re-evaluated by two other experienced examiners. Interobserver and intraobserver variabilities for echocardiogram measurements were assessed and disclosed less than 8% changes. Left ventricular mass (LMV) was calculated by using the Devereux and Reichek formula, according to Penn convention. 19 The LVMI was
, where IVS is the thickness of the septum (cm); LVDd is the left ventricular diastolic internal diameter (cm); PW is the thickness of the posterior wall (cm); and BSA is the body surface area (m 2 ). Myocardial hypertrophy was defined as a myocardial mass index 4150 g m À2 in men and 4120 g m À2 in women. 19 
Aerobic training program
The aerobic training program comprised intermittent activity (walking and/or aerobic running), depending on the activity planned for the session and individual response conditions for training load, with a minimum of three 60-min weekly sessions with a total of 12 months. Uninterrupted exercise was used in the sessions. Heart rate was used for effort estimation, with the usual standard. 16 All subjects receiving training took part in an introductory mesocycle aiming at adapting passive locomotion system, especially during the first two weeks. Afterwards, a program was started with 60% of the maximum heart rate reached in the treadmill stress test and ended with stimuli between 85 and 90% of the maximum heart rate. 
Statistical analysis
Results
Out of the 245 subjects initially included in the study protocol, 195 (physical exercise, n ¼ 39; rilmenidine, n ¼ 38; atenolol, n ¼ 40; enalapril, n ¼ 36; losartan, n ¼ 42) concluded the treatment within 12 months. There was no significant difference between the groups regarding anthropometric and clinical characteristics and in complementary tests within the basal and 12-month periods (Table 1) .
Changes in blood pressure at rest and at peak effort There were significant differences when groups were compared within groups. Systolic blood pressure reduction at rest was À9% (135±5 to 123 ± 6 mmHg) in the atenolol group, À8.6% (134 ± 5 to 122 ± 7 mm Hg) in the enalapril group and À8% (133±5 to 123±6 mm Hg) in the losartan group, but no statistically significant differences in the post-test values were noticed between these three groups (P40.05). The reduction in the physical exercise group was À2.9% (132 ± 5 to 128 ± 7 mm Hg) and in the rilmenidine group À4.2% (135 ± 4 to 129±7 mm Hg), with no statistically significant differences between these two groups (P40.05). Nevertheless, SBP reduction at rest in the atenolol, enalapril and losartan groups was greater and statistically significant when compared with the physical exercise and rilmenidine groups (Po0.001, Figure 1 ). Systolic blood pressure reduction at peak effort was À18.7% (225 ± 5 to 183 ± 10 mm Hg) in the atenolol group, À19.4% (225 ± 5 to 182 ± 9 mm Hg) in the enalapril group and À18.5% (225±3 to 184 ± 10 mm Hg) in the losartan group, with no statistically significant difference in the post-test values among the three groups (P40.05). The physical exercise group showed a reduction of À13.9% (225 ± 4 to 193 ± 11 mm Hg) similar to the rilmenidine group, À15.6% (226 ± 6 to 191±12 mm Hg). Blood pressure reduction at peak effort was greater and statistically significant in the post-test values in the atenolol, enalapril and losartan groups when compared with the physical exercise and rilmenidine groups (Po0.001, Figure 2 ).
Changes in heart rate at rest and at peak effort Resting heart rate reduction was À5.2% (79±9 to 75±2 bpm) in the physical exercise group, À5.8% (81 ± 8 to 76 ± 1 bpm) in the rilmenidine group, À6.2% (79±9 to 74±2 bpm) in the enalapril group and -5.8% (78±7 to 73±2 bpm) in the losartan group, with no statistically significant difference among the four groups (P40.05). A more pronounced reduction of heart rate at rest occurred in the atenolol group compared with the other groups (Po0.001, Figure 3 ). The reduction was À16.9% (78 ± 8 to 65 ± 1 bpm).
The reduction of heart rate at peak effort was À3.9% (179±8 to 172±7 bpm) in the physical exercise group, -2.6% (184 ± 7 to 179 ± 6 bpm) in the rilmenidine group and À3.6% (181 ± 7 to 174±7 bpm) in the losartan group, with no Figure 2 Confidence interval of 95% for the difference between baseline and after 12 months of treatment for systolic blood pressure at peak effort. *Po0.001 versus physical exercise and rilmenidine. statistically significant difference between the groups (P40.05). The reduction in the enalapril group was À4.2% (181±7 to 173±7 bpm), with no statistically significant difference when comparing this group with the losartan and physical exercise groups (P40.05). However, there was a more pronounced and statistically significant reduction when comparing this group with the rilmenidine group (Po0.001). The reduction of heart rate at peak effort in the atenolol group was À11.4% (176±7 to 156 ± 7 bpm), more pronounced and statistically significant when compared with the other groups (Po0.001, Figure 4 ). The improvement of VO 2 max (maximum oxygen consumption) at 12 months of follow-up was 20% (40.4 ± 3.2 to 48.4 ± 3.5 ml kg À1 min À1 ) and was only observed in the physical exercise group.
Changes in left ventricular mass index
The reduction of LVMI was À2.98% (136.7±10.1 to 132.8±10.4 g m À2 ) in the physical exercise group and -5.14% (135.7 ± 10.2 to 129.0 ± 9.4 g m À2 ) in the rilmenidine group, with no statistically significant difference between the two groups (P40.05). The reduction in the atenolol group was À7.25 (134.0 ± 8.9 to 125.2 ± 9.6 g m À2 ), more pronounced and statistically significant than in the physical exercise group (Po0.01), but similar to the rilmenidine group (P40.05). The reduction in the enalapril group was À28.25% (137.0±8.8 to 107.1±9.4 g m À2 ) and in the losartan group À26.93% (136.0±8.7 to 107.7 ± 10.6 g m À2 ), with no statistically significant difference between the two groups. However, when compared with the physical exercise, rilmenidine and atenolol groups, a more pronounced and statistically significant reduction can be observed in the enalapril and losartan groups (Po0.001, Figure 5 ).
Discussion
Early diagnosis of arterial hypertension, preferrably in the prehypertensive phase, is highly significant for the prognosis of the disease. 20 The exaggerated increase in blood pressure during the treadmill Figure 4 Confidence interval of 95% for the difference between baseline and after 12 months of treatment for heart rate at peak effort. *Po0.001 versus physical exercise, rilmenidine, enalapril and losartan. **Po0.05 versus rilmenidine. Figure 3 Confidence interval of 95% for the difference between baseline and after 12 months of treatment for heart rate at rest. *Po0.001 versus physical exercise, rilmenidine, enalapril and losartan.
Differences in LVMI
stress test predisposes the subject to a higher risk of developing hypertension in the future. [21] [22] [23] There is a significant correlation between exaggerated blood pressure response during physical effort in normotense subjects and lesion of target organ, especially LVH. 24 The probable physiopathological mechanism of such phenomenon in normotense subjects points out to the participation of the SNS and/or RAS. 9 The main interest in this study was to evaluate the influence of the neurohumoral system in the reduction of LVH in those subjects.
In the five groups there was a reduction in SBP at rest and at peak effort over the 12 months of treatment. However, the groups that were treated with atenolol, enalapril and losartan had a higher reduction in SBP than the physical exercise and rilmenidine groups. The reduction in left ventricular mass was similar in the enalapril and losartan groups, but these two groups had higher and statistically significant left ventricular mass reduction when compared to the physical exercise, atenolol and rilmenidine groups.
In the literature, there are no studies evaluating any type of therapeutical intervention in LVH reduction within this specific group of subjects. Nevertheless, our results are similar to the ones found when left ventricular mass reduction is evaluated in hypertensive and LVH subjects. 25, 26 We observed that drugs blocking the RAS-angiotensin system were more effective than those blocking the SNS regarding LVH regression.
Physical exercise was reported to be efficient in SBP and DBP reduction at rest, 27 to decrease sympathetic activity or even to cause parasympathetic stimulus, 28 but there is no significant LVH reduction with this type of treatment. 29, 30 Our results are similar to those found in the literature, for even when considering our effective program, physical exercise has not reported to be isolatedly effective in LVH reduction. Left ventricular mass reduction was similar when comparing an angiotensin-converting enzyme inhibitor (enalapril) with an angiotensin AT1 receptor antagonist (losartan) for the same percentage of blood pressure reduction, results similar to those found in the literature. 31 Drugs that block the RAS (enalapril and losartan) were more efficient than betablockers (atenolol) in LVH regression for the same blood pressure reduction percentage, results once again similar to those found in the literature. 32 The use of an antagonist to the imidazolinic receptor (rilmenidine) did not effectively block SNS compared with atenolol, and, in spite of literature on LVH reduction with that drug, 33 we could not reproduce such results.
Atenolol was found to be similar to losartan and enalapril in blood pressure control both at rest and at peak effortt, being more efficient in heart rate reduction than in any other treatment mode ( Figures  3 and 4) . The atenolol group showed an effective SNS block, higher and statistically significant than the others, but when we evaluated the LVMI reduction, the treatment with losartan and enalapril was found to be more efficient.
Angiotensin II seems to promote myocytes growth by activating the AT 1 receptor. 34 It is known that the adrenergic activation stimulates the myocardial growth. 35, 36 Also, there is an important interaction between RAS and SNS. Angiotensin II increases the release of norepinephrine in presynaptic junctions, increases the pressure response to norepinephrine and increases the sympathetic tonus. 37 One of the hypotheses for the result found was that in such subjects the trigger for the development of LVH would be a RAS hyperactivity, or its predominance over the SNS. This initial hypothesis we present seems to be in accordance with what Polonia et al. 8 assumed when, following catecolamine dosage in subjects with such characteristics, they suggested the hypothesis of sympathetic hyperactivity for such phenomenon. However, the RAS activity was not evaluated in that study. A second hypothesis to justify our results could be the data found by Fossum et al., 38 showing losartan to be more effective than atenolol in LVH reduction and demonstrating the efficiency of both drugs in sympathetic blocking. Thus, blocking SNS could be added to the effect produced by enalapril and losartan on RAS. Lim et al.'s study 9 showed RAS hyperactivation in such subjects, since it disclosed an important correlation between aldosterone/renin ratio and SBP during physical exercise. Another hypothesis to be taken into account is the possibility of those subjects having some type of genetic polymorphism for RAS components, as Schunkert et al. 39 were able to show a stronger association of genotype DD and LVH in subjects with normal blood pressure.
An important limitation of our study was an absence of a control group with subjects without any treatment. Our comparison of the effect of such drugs in prehypertensive subjects could be taken as another limitation, since literature has evaluated the effect of such drugs in hypertensive subjects. Despite considering dosage of serum and/or urinary concentrations of RAS catecholamines and peptides more trustworthy for hypotheses evaluation, we know that such values may be influenced by several variables.
We suggest subjects with the same characteristics as the ones included in our protocol should be studied from a genetic standpoint.
Another question that may be answered in the future is: knowing LVH is an independent risk factor of mortality and taking into consideration the great prevalence of sustained hypertension in this group of subjects in the future, should we start treating them with drugs? These results suggest that RAS is related to the genesis of LVH of hyperreactive subjects and that drugs blocking RAS are more effective in LVH regression in such subjects than drugs blocking SNS, regardless of blood pressure reduction at rest and at peak effort.
